



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(Patent Law Article 12, Implementing Regulation No. 56)

(PCT Article 36 and Rule 70)


RECEIVED

APR 17 2002

TECH CENTER 1600/2900

Applicant's or agent's file reference 2634WOOP		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).																									
International application No. <b>PCT/JP00/05685</b>	International filing date 24 August 2000	Priority Date 27 August 1999																									
International Patent Classification (IPC) or national classification and IPC <b>Int. Cl.<sup>7</sup></b> C12N 15/09, C07K 14/705, C07K 16/28, C12N 1/15, C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/02, C12P 21/08, C12Q 1/68, A61K 45/00, A61P 43/00																											
Applicant <b>TAKEDA CHEMICAL INDUSTRIES, LTD.</b>																											
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <b>3</b> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of      sheet(s).</p>																											
<p>3. This report contains indications relating to the following items:</p> <table border="0"><tr><td>I</td><td><input checked="" type="checkbox"/></td><td>Basis of the report</td></tr><tr><td>II</td><td><input type="checkbox"/></td><td>Priority</td></tr><tr><td>III</td><td><input type="checkbox"/></td><td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td></tr><tr><td>IV</td><td><input type="checkbox"/></td><td>Lack of unity of invention</td></tr><tr><td>V</td><td><input checked="" type="checkbox"/></td><td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td></tr><tr><td>VI</td><td><input type="checkbox"/></td><td>Certain documents cited</td></tr><tr><td>VII</td><td><input type="checkbox"/></td><td>Certain defects in the international application</td></tr><tr><td>VIII</td><td><input type="checkbox"/></td><td>Certain observations on the international application</td></tr></table>				I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																									
II	<input type="checkbox"/>	Priority																									
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																									
IV	<input type="checkbox"/>	Lack of unity of invention																									
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																									
VI	<input type="checkbox"/>	Certain documents cited																									
VII	<input type="checkbox"/>	Certain defects in the international application																									
VIII	<input type="checkbox"/>	Certain observations on the international application																									
Date of submission of the demand 29 September 2000		Date of completion of this report 20 August 2001																									
Name and mailing address of the IPEA/JP  JAPAN PATENT OFFICE KASUMIGASEKI 3-4-3, CHIYODA-KU, TOKYO, JAPAN Postal Code 100-8915		Patent Office Examiner (Authorized Officer)  JUNKO KIMURA  Telephone No. (03) 3581-1101 ext. 3488	4N      9641																								





**V. Reasoned statement under PCT Article 35(2) (Patent Law Article 12) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. STATEMENT**

Novelty (N)	Claims	YES
	Claims 1-14	NO
Inventive step (IS)	Claims	YES
	Claims 1-14	NO
Industrial applicability (IA)	Claims 1-14	YES
	Claims	NO

**2. CITATIONS AND EXPLANATIONS (Rule 70.7)**

**Claims 1-14**

The inventions of claims 1-14 do not have novelty over citation 1 (WO 98/46620, A1 (MILLENNIUM PHARMACEUTICALS, INC.) October 22 1998).

In citation 1, the amino acid sequence of a novel G protein-coupled receptor protein as well as the base sequence of DNA encoding the protein is described.

The amino acid sequence of a G protein-coupled receptor protein described in citation 1 has high homology with the amino acid sequence represented by SEQ ID NO:1 of the subject application. Therefore, as the invention of the subject application relates to a protein comprising an amino acid sequence that is substantially the same as the amino acid sequence represented by SEQ ID NO:1, it cannot be recognized that there exists a substantial difference between the invention of the subject application and the invention described in citation 1.

RECEIVED

APR 17 2002

TECH CENTER 1600 2901